DiaMedica Therapeutics Inc
DMAC6.760USD
-0.110-1.60%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
291.17MMarket Cap
LossP/E TTM
More Details of DiaMedica Therapeutics Inc Company
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.
Company Info
Ticker SymbolDMAC
Company nameDiaMedica Therapeutics Inc
IPO dateJan 04, 2008
CEOMr. Rick Pauls
Number of employees27
Security typeOrdinary Share
Fiscal year-endJan 04
Address301 Carlson Parkway
CityMINNEAPOLIS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code55305
Phone17634965454
Websitehttps://www.diamedica.com/
Ticker SymbolDMAC
IPO dateJan 04, 2008
CEOMr. Rick Pauls
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Kellen
Mr. Scott Kellen
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
32.29K
--
Mr. David J. (Dave) Wambeke
Mr. David J. (Dave) Wambeke
Chief Business Officer
Chief Business Officer
--
--
Mr. Daniel J. (Dan) O'Connor, J.D.
Mr. Daniel J. (Dan) O'Connor, J.D.
Independent Director
Independent Director
--
--
Ms. Tanya N. Lewis
Ms. Tanya N. Lewis
Independent Director
Independent Director
--
--
Mr. James T. (Jim) Parsons, CPA
Mr. James T. (Jim) Parsons, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Rick Pauls
Mr. Rick Pauls
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Charles P. Semba, M.D.
Dr. Charles P. Semba, M.D.
Independent Director
Independent Director
--
--
Dr. Richard E. Kuntz, M.D.
Dr. Richard E. Kuntz, M.D.
Independent Director
Independent Director
--
--
Dr. Michael Giuffre, M.D.
Dr. Michael Giuffre, M.D.
Independent Director
Independent Director
--
--
Dr. Julie Krop, M.D.
Dr. Julie Krop, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Scott Kellen
Mr. Scott Kellen
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
32.29K
--
Mr. David J. (Dave) Wambeke
Mr. David J. (Dave) Wambeke
Chief Business Officer
Chief Business Officer
--
--
Mr. Daniel J. (Dan) O'Connor, J.D.
Mr. Daniel J. (Dan) O'Connor, J.D.
Independent Director
Independent Director
--
--
Ms. Tanya N. Lewis
Ms. Tanya N. Lewis
Independent Director
Independent Director
--
--
Mr. James T. (Jim) Parsons, CPA
Mr. James T. (Jim) Parsons, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Rick Pauls
Mr. Rick Pauls
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EQT Partners AB
16.22%
Trill AB,LLC.
15.02%
Jacinto (Richard II)
9.59%
Cooperman (Leon G)
6.02%
B. Riley Asset Management, LLC
4.27%
Other
48.88%
Shareholders
Shareholders
Proportion
EQT Partners AB
16.22%
Trill AB,LLC.
15.02%
Jacinto (Richard II)
9.59%
Cooperman (Leon G)
6.02%
B. Riley Asset Management, LLC
4.27%
Other
48.88%
Shareholder Types
Shareholders
Proportion
Individual Investor
17.47%
Private Equity
16.22%
Corporation
15.02%
Investment Advisor
9.13%
Investment Advisor/Hedge Fund
7.11%
Family Office
3.19%
Hedge Fund
1.26%
Research Firm
0.62%
Pension Fund
0.07%
Other
29.91%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
106
25.51M
59.66%
+2.79M
2025Q1
107
25.07M
58.63%
+2.30M
2024Q4
97
24.18M
56.77%
+6.94M
2024Q3
88
23.30M
54.97%
+6.30M
2024Q2
83
22.90M
54.03%
+4.63M
2024Q1
86
18.34M
46.95%
+3.85M
2023Q4
86
17.52M
44.84%
+2.93M
2023Q3
87
18.82M
49.67%
+3.65M
2023Q2
90
18.06M
47.71%
+3.46M
2023Q1
89
11.51M
43.51%
-2.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EQT Partners AB
5.53M
12.89%
--
--
Mar 18, 2025
Trill AB,LLC.
5.22M
12.18%
--
--
Mar 18, 2025
Jacinto (Richard II)
4.56M
10.63%
--
--
Mar 18, 2025
B. Riley Asset Management, LLC
2.21M
5.14%
+2.21M
--
Jun 28, 2024
Omega Advisors, Inc.
1.63M
3.79%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.35M
3.15%
+109.36K
+8.80%
Mar 31, 2025
Paragon JV Partners, LLC
600.00K
1.4%
+85.22K
+16.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
315.74K
0.74%
+9.99K
+3.27%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
